|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The occurrence of five sense mutations [S391A, G397A, L402F and M405T in the hypervariable region 1 (HVR1) of envelope glycoprotein 2 and I2750M in NS5B] suggested that HCV undergoes genetic evolution during culture.
|
28758632 |
2017 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used a bioinformatics and functional approach to investigate whether E1/E2 envelope glycoprotein structure and function were associated with treatment failure in 92 patients infected with HCV genotype 1.
|
23335805 |
2013 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we rescued a recombinant PR8 influenza viral vector, called rgFLU-HCV<sub>CE1E2</sub>, carrying the core and envelope glycoprotein (C/E1/E2) epitopes of HCV inserted into the influenza nonstructural protein 1 gene.
|
28778831 |
2017 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The HCV polyprotein contains a hypervariable region (HVR1) located at the N terminus of the second envelope glycoprotein E2.
|
11356980 |
2001 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hypervariable region I (HVRI) of the putative second envelope glycoprotein (gp70) of hepatitis C virus (HCV) undergoes sequential alterations at intervals of several months during the chronic phase of hepatitis.
|
7515022 |
1994 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recombinant baculoviruses that produce a putative non-structural protein 1 (NS1) of hepatitis C virus (HCV), predicted to be the second envelope glycoprotein, were constructed.
|
7686870 |
1993 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon.
|
10915068 |
2000 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.
|
1314389 |
1992 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The hypervariable region 1 (HVR1) of the putative second envelope glycoprotein (gp70) of hepatitis C virus (HCV) contains a sequence-specific immunological B-cell epitope that induces the production of antibodies restricted to the specific viral isolate, and anti-HVR1 antibodies are involved in the genetic drift of HVR1 driven by immunoselection (N. Kato, H. Sekiya, Y. Ootsuyama, T. Nakazawa, M. Hijikata, S. Ohkoshi, and K. Shimotohno, J. Virol.67:3923-3930, 1993).
|
7518526 |
1994 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.
|
29128754 |
2018 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hepatitis C virus (HCV) genome shows extensive sequence diversity at 2 hypervariable regions (HVR1 and HVR2) of the putative envelope glycoprotein (gp70).
|
8314302 |
1994 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Assembly of infectious hepatitis C virus (HCV) particles is known to involve host lipoproteins, giving rise to unique lipo-viro-particles (LVPs), but proteome studies now suggest that additional cellular proteins are associated with HCV virions or other particles containing the viral envelope glycoprotein E2.
|
30880226 |
2019 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The quasispecies of HCV showed various secondary structures of HVR1, but many sequences seemed to have common characteristics. beta sheet conformations around both the N-terminus and position 20 (numbered from the NH2 terminus of E2 envelope glycoprotein), and/or coil structures around the C-terminus of HVR1 could be identified.
|
12010507 |
2002 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection.
|
8382721 |
1993 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
|
26278021 |
2016 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient.
|
8143975 |
1994 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
|
24965471 |
2014 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings indicate that the antibody response to HCV E2 is affected by the genotype of the virus and that induction of a strong humoral immune response to HCV E2 may contribute to a decreased viral load.
|
11505439 |
2001 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antibodies against envelope glycoprotein 1 and 2 (anti-E1/E2) have been suggested to influence HCV replication levels.
|
15042645 |
2004 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Confocal analysis showed that accumulation of occludin in the ER partially co-localized with HCV envelope glycoprotein E2.
|
18802961 |
2008 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
TNF inhibits HCV infection despite increased HCV envelope glycoprotein-mediated infection of liver cells.
|
28456632 |
2017 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hypervariable region 1 (HVR1) that includes the first 27 amino acid residues of the E2 envelope glycoprotein is the most variable region within the HCV polyprotein.
|
22927442 |
2012 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report the generation and application of a combinatorial library of HCV strain JFH1 envelope glycoprotein to profile the antibody response in four HCV chronically infected individuals.
|
25274855 |
2015 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our phase I study with recombinant HCV E1/E2 envelope glycoprotein (EnvGPs) as a candidate vaccine did not induce a strong immune response in volunteers.
|
29443378 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein.
|
29951061 |
2018 |